Skip to main content

Table 1 Baseline characteristics of PAF and PsAF patients underwent circRNA microarray analysis

From: The potential regulatory role of hsa_circ_0004104 in the persistency of atrial fibrillation by promoting cardiac fibrosis via TGF-β pathway

 

PsAF (n = 6)

PAF (n = 6)

p value

Age, years

59.33 ± 6.09

58.67 ± 4.89

0.838

Male, n (%)

3 (50.0)

3 (50.0)

1.000

BMI, kg/m2

27.25 ± 1.47

25.45 ± 2.33

0.140

Heart rate, bpm

95.50 ± 18.21

87.00 ± 18.22

0.438

CAD, n (%)

0 (0)

1 (16.7)

1.000

HTN, n (%)

5 (83.3)

4 (66.7)

1.000

DM, n (%)

2 (33.3)

1 (16.7)

1.000

Smoke, n (%)

2 (33.3)

0 (0)

0.455

AF duration, months

9.2 ± 2.7

7.8 ± 3.1

0.291

LAD, mm

38.83 ± 5.67

39.00 ± 3.90

0.954

LVEF, %

64.50 ± 4.46

68.67 ± 5.39

0.175

LVEDD, mm

46.00 ± 4.05

47.92 ± 3.01

0.374

HbA1c, %

6.18 ± 1.03

5.86 ± 0.46

0.507

LDL, mmol/L

2.80 ± 0.42

2.87 ± 1.58

0.922

Creatine, µmol/L

64.98 ± 20.70

63.02 ± 17.55

0.863

BNP, pg/ml

1336.17 ± 806.4

1211.02 ± 741.18

0.385

β-blockers, n (%)

4 (66.7)

3 (50.0)

1.000

  1. Data are number (%) and mean ± SD
  2. PsAF, persistent atrial fibrillation; PAF, paroxysmal atrial fibrillation; BMI, body mass index; bpm, beats per minute; CAD, coronary artery disease; HTN, hypertension; DM, diabetes mellitus; AF, atrial fibrillation; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; HbA1c, glycosylated hemoglobin; LDL, low density lipoprotein